Sao Paulo (Vax-Before-Travel News)

In response to the serious health threat posed by Dengue fever in the Americas, the Pan American Health Organization has been actively working since 2003 to control and prevent the impact of this mosquito-borne disease.

One key prevention strategy is vaccination, which the introduction of next-generation vaccines, such as Butantan-DV, has enhanced.

This live attenuated tetravalent vaccine is designed to target all four Dengue virus (DENV) serotypes. Heterotypic Dengue infections—those occurring with a different serotype after previous exposure—have been shown to increase the risk of severe disease, highlighting the necessity for broad, serostatus-independent protection.

The newly approved single-dose Dengue vaccine, developed by Brazil’s Butantan Institute, has recently demonstrated sustained protection for 5 years in a large phase 3 clinical trial. The primary aim of the trial was to assess the vaccine’s efficacy against symptomatic Dengue, confirmed by reverse transcription PCR, from any serotype.

During the five-year follow-up period (2016–2024), the overall vaccine efficacy was 65% (95% CI: 57.8–71.0%) starting 28 days post-vaccination, regardless of prior DENV infection.

Moreover, the vaccine’s efficacy against severe outcomes was reported at 80.5% (95% CI: 50.8–92.4%) for Dengue cases that presented warning signs or severe Dengue.

Importantly, Butantan-DV safety data remained reassuring over the long term.

The results of this double-blind, placebo-controlled study were published in Nature Medicine on March 4, 2026, and involved over 16,000 participants aged 2 to 59 years in Brazil from 2016 to 2019.

Regarding access to this innovative vaccine, in February 2026, the Ministry of Health launched a vaccination campaign for healthcare professionals the protect 1.2 million frontline workers. General vaccinations in Brazil are expected to increase, stemming from a strategic partnership between Brazil and China that involves the transfer of national technology to WuXi Vaccines.

This cooperation could increase national vaccine production by up to 30 times, the researchers wrote.

In the United States, a first-generation vaccine has been offered in Puerto Rico, where Dengue has become endemic.